1 Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine , Seoul, Korea.
2 Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine , Seoul, Korea.
Thyroid. 2018 Apr;28(4):504-510. doi: 10.1089/thy.2017.0382. Epub 2018 Mar 16.
Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is an indolent thyroid tumor previously known as noninvasive subtype of encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC). The absence of BRAF mutations has been considered characteristic of NIFTPs. However, a recent study from Korea found that 28.6% of NIFTPs harbored a BRAF mutation. This study evaluated BRAF and RAS mutations in NIFTPs and invasive subtype of EFVPTCs.
This study enrolled 32 patients with NIFTP and 48 with invasive EFVPTC. BRAF, NRAS, HRAS, and KRAS mutations were evaluated by direct sequencing using DNA from fresh-frozen tissues and formalin-fixed, paraffin-embedded tissue samples.
The primary tumor size of NIFTP was smaller than that of invasive EFVPTC (median 2.8 cm vs. 3.2 cm; p = 0.03). Cervical lymph node metastases were found in only four (8%) patients with invasive EFVPTC. There was no BRAF mutation in NIFTPs, whereas invasive EFVPTCs had three (6%) BRAF mutations and one (2%) BRAF mutation. RAS mutations were detected in 15 (47%) NIFTPs and 22 (46%) invasive EFVPTCs. NRAS mutations in codon 61 were the most common mutations in NIFTPs (34%) and invasive EFVPTCs (27%). There was no significant difference in the frequency of RAS mutations between the two groups.
There was no BRAF mutation in any of the NIFTPs. RAS mutations, particularly mutations in codon 61 of NRAS, were the most common mutations in both NIFTPs and invasive EFVPTCs. The presence of a RAS mutation is not helpful for preoperative differentiation between NIFTPs and invasive EFVPTCs.
非侵袭性滤泡甲状腺肿瘤伴乳头状核特征(NIFTP)是一种惰性甲状腺肿瘤,以前称为包膜内滤泡型甲状腺乳头状癌的非侵袭性亚型(EFVPTC)。BRAF 突变缺失被认为是 NIFTP 的特征。然而,最近来自韩国的一项研究发现,28.6%的 NIFTP 存在 BRAF 突变。本研究评估了 NIFTP 和侵袭性 EFVPTC 中的 BRAF 和 RAS 突变。
本研究纳入了 32 例 NIFTP 患者和 48 例侵袭性 EFVPTC 患者。通过直接测序评估新鲜冷冻组织和福尔马林固定石蜡包埋组织样本中的 BRAF、NRAS、HRAS 和 KRAS 突变。
NIFTP 的原发肿瘤直径小于侵袭性 EFVPTC(中位数 2.8cm 比 3.2cm;p=0.03)。仅 4 例(8%)侵袭性 EFVPTC 患者发生颈部淋巴结转移。NIFTP 中未发现 BRAF 突变,而侵袭性 EFVPTC 中有 3 例(6%)BRAF 突变和 1 例(2%)BRAF 突变。在 15 例(47%)NIFTP 和 22 例(46%)侵袭性 EFVPTC 中检测到 RAS 突变。NIFTP 和侵袭性 EFVPTC 中最常见的 RAS 突变是 NRAS 密码子 61 突变(分别为 34%和 27%)。两组间 RAS 突变频率无显著差异。
NIFTP 中均未发现 BRAF 突变。RAS 突变,尤其是 NRAS 密码子 61 突变,是 NIFTP 和侵袭性 EFVPTC 中最常见的突变。RAS 突变的存在无助于术前区分 NIFTP 和侵袭性 EFVPTC。